Connor, Clark & Lunn Investment Management (CC&L)
ENTA icon

Connor, Clark & Lunn Investment Management (CC&L)’s Enanta Pharmaceuticals ENTA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Buy
153,008
+27,249
+22% +$366K ﹤0.01% 976
2026
Q1 		$1.59M Buy
125,759
+21,856
+21% +$293K ﹤0.01% 1022
2025
Q4 		$1.64M Buy
103,903
+26,397
+34% +$335K ﹤0.01% 984
2025
Q3 		$928K Buy
77,506
+62,710
+424% +$501K ﹤0.01% 1087
2025
Q2 		$112K Sell
14,796
-15,669
-51% -$94.3K ﹤0.01% 1455
2025
Q1 		$168K Buy
30,465
+5,829
+24% +$36K ﹤0.01% 1337
2024
Q4 		$142K Buy
24,636
+12,868
+109% +$123K ﹤0.01% 1351
2024
Q3 		$122K Buy
+11,768
New +$154K ﹤0.01% 1362
2024
Q2 		– Sell
-44,629
Closed -$779K – 1471
2024
Q1 		$779K Buy
44,629
+3,264
+8% +$43.2K ﹤0.01% 960
2023
Q4 		$389K Buy
+41,365
New +$385K ﹤0.01% 1114
2022
Q4 		– Sell
-5,110
Closed -$265K – 1278
2022
Q3 		$265K Buy
+5,110
New +$299K ﹤0.01% 940
2020
Q3 		– Sell
-9,911
Closed -$498K – 980
2020
Q2 		$498K Buy
+9,911
New +$513K ﹤0.01% 756
2019
Q4 		– Sell
-7,950
Closed -$478K – 968
2019
Q3 		$478K Buy
7,950
+5,300
+200% +$394K ﹤0.01% 693
2019
Q2 		$224K Buy
+2,650
New +$238K ﹤0.01% 883
2019
Q1 		– Sell
-3,100
Closed -$220K – 945
2018
Q4 		$220K Sell
3,100
-1,200
-28% -$92K ﹤0.01% 831
2018
Q3 		$367K Buy
+4,300
New +$431K ﹤0.01% 752
2015
Q1 		– Sell
-5,300
Closed -$270K – 585
2014
Q4 		$270K Sell
5,300
-4,200
-44% -$188K ﹤0.01% 477
2014
Q3 		$376K Buy
+9,500
New +$379K ﹤0.01% 424
2014
Q2 		– Sell
-10,000
Closed -$441K – 559
2014
Q1 		$441K Buy
+10,000
New +$363K ﹤0.01% 504

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Connor, Clark & Lunn Investment Management (CC&L)'s ENTA Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Enanta Pharmaceuticals (ENTA) stake by 22% in Q2 2026, buying an estimated $366K and bringing the position to 153,008 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #976.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ENTA in Q1 2014 and has held it in 19 quarters since. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 153,008 shares of Enanta Pharmaceuticals worth $2.23M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 27,249 Enanta Pharmaceuticals shares in Q2 2026, an estimated $366K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #976 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Enanta Pharmaceuticals in Q1 2014 and has held it in 19 quarters since.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.